C3 and atypical hemolytic-uremic syndrome: The different response is due to the correct blockage of the terminal complement pathway in AHUS, whereas this therapy is questionable in patients with C3 GP because the disease is characterized by abnormal activation of the alternative complement pathway, abnormal cleavage of C3 and continuous deposition of C3 split products in glomeruli.